Elevance Health, Inc. (ELV) Stock Analysis — Fair Value, Risk & Moat Rating
NYQ · Healthcare · Healthcare Plans
Is Elevance Health, Inc. a safe investment right now?
Elevance Health, Inc.'s Altman Z-Score of 2.83 places it in the gray zone. Our fair value estimate is $299.96 (Fairly Valued). Moat rating: 3.4/5 stars.
Could Elevance Health, Inc. go bankrupt? Altman Z-Score analysis
Z-Score of 2.83 places the company in the gray zone (1.8-3.0), warranting closer scrutiny.
- Below 1.8 — Distress Zone (high bankruptcy risk)
- 1.8 to 3.0 — Gray Zone (elevated uncertainty)
- Above 3.0 — Safe Zone (financially healthy)
What drives ELV's Z-Score?
| Component | Formula | Value | Weight | Contribution |
|---|---|---|---|---|
| A · Working Capital / Total Assets | WC / TA | 0.0 | 1.2 | 0.0 |
| B · Retained Earnings / Total Assets | RE / TA | 0.2913 | 1.4 | 0.41 |
| C · EBIT / Total Assets | EBIT / TA | 0.0668 | 3.3 | 0.22 |
| D · Market Cap / Total Liabilities | MCap / TL | 0.935 | 0.6 | 0.56 |
| E · Revenue / Total Assets | Rev / TA | 1.639 | 1.0 | 1.64 |
How has ELV's financial health changed over time?
| Year | Z-Score | Zone |
|---|---|---|
| 2022 | 2.85 | Gray |
| 2023 | 2.87 | Gray |
| 2024 | 2.75 | Gray |
| 2025 | 2.83 | Gray |
Source: Calculated from ELV's latest 10-K filing on SEC EDGAR.
What is Elevance Health, Inc. actually worth?
How we calculated this
| Input | Value | Source |
|---|---|---|
| Predicted EPS (α) | $25.42 | Proprietary blend of reported actuals + analyst consensus, weighted by α |
| Last Year EPS | $25.21 | Annual report (SEC EDGAR) |
| Analyst Consensus EPS (This Year) | $25.75 | 21 analysts consensus |
| Trailing P/E | 13.9x | Current market pricing |
| Fair P/E (β discount) | 11.8x | Trailing PE adjusted by value discount factor β, hard-capped |
| Earnings Trend (γ) | Growing | Directional signal: predicted vs trailing EPS |
Wall Street Reference: Analyst consensus target price is $378.19 (21 analysts). This is shown for reference only and is not used in our valuation model.
Source: Earnings data from SEC EDGAR filings. Market data via Yahoo Finance.
Does Elevance Health, Inc. have a durable competitive advantage?
Moat rating: 3.4/5.
What makes up ELV's moat score?
ROIC Stability
ROIC variability over the past decade. Score: 4/5.
Gross Margin Trend
Gross margin trajectory over the past decade. Score: 3/5.
Switching Costs
Estimated customer lock-in based on margin level. Score: 3/5.
How stable is ELV's return on invested capital?
| Year | ROIC | Trend |
|---|---|---|
| 2022 | 14.0% | — |
| 2023 | 13.6% | Stable |
| 2024 | 12.5% | Declining |
| 2025 | 10.7% | Declining |
Source: ROIC calculated from SEC EDGAR filings.
Is Elevance Health, Inc.'s dividend safe?
Can Elevance Health, Inc. afford its dividend?
Payout ratio is 29.0%. FCF covers the dividend 5.9x. 16 consecutive years of payments.
Elevance Health, Inc.'s key financial metrics
| Metric | Latest | 1Y Ago | 3Y Ago | Trend |
|---|---|---|---|---|
| Revenue | $199.1B | $176.8B | $156.6B | Rising |
| Net Income | $5.7B | $6.0B | $5.9B | Stable |
| Free Cash Flow | $3.2B | $4.6B | $7.2B | Declining |
Recent events that affect our ELV analysis
ELV analyst consensus: 59% bullish (13 of 22 analysts)
3 Strong Buy, 10 Buy, 9 Hold, 0 Sell, 0 Strong Sell. Consensus target: $378.19 (15.2% upside). Compare with our independent Fair Value: $299.96.
ELV beat EPS estimates by 16.4%
Reported EPS: $12.58 vs estimate $10.81. Earnings strength supports our Fair Value of $299.96 (8.6% below current price).
ELV filed quarterly report (10-Q)
Quarterly update with interim financials. May signal changes to earnings trajectory and balance sheet health. View on SEC EDGAR →
ELV filed 8-K (material event)
8-K filings disclose material events — acquisitions, leadership changes, or guidance revisions that may affect valuation. View on SEC EDGAR →
ELV filed 8-K (material event)
8-K filings disclose material events — acquisitions, leadership changes, or guidance revisions that may affect valuation. View on SEC EDGAR →
ELV paid $1.7200/share dividend
Dividend Safety Grade: A. Payout ratio: 29.0%.
ELV filed 8-K (material event)
8-K filings disclose material events — acquisitions, leadership changes, or guidance revisions that may affect valuation. View on SEC EDGAR →
ELV filed 8-K (material event)
8-K filings disclose material events — acquisitions, leadership changes, or guidance revisions that may affect valuation. View on SEC EDGAR →
ELV filed annual report (10-K)
Annual filing with full-year financials. Our Altman Z-Score, Moat, and Fair Value models are derived from this data. View on SEC EDGAR →
ELV beat EPS estimates by 7.7%
Reported EPS: $3.33 vs estimate $3.09. Earnings strength supports our Fair Value of $299.96 (8.6% below current price).
ELV filed 8-K (material event)
8-K filings disclose material events — acquisitions, leadership changes, or guidance revisions that may affect valuation. View on SEC EDGAR →
ELV filed 8-K (material event)
8-K filings disclose material events — acquisitions, leadership changes, or guidance revisions that may affect valuation. View on SEC EDGAR →
ELV paid $1.7100/share dividend
Dividend Safety Grade: A. Payout ratio: 29.0%.
ELV filed 8-K (material event)
8-K filings disclose material events — acquisitions, leadership changes, or guidance revisions that may affect valuation. View on SEC EDGAR →
ELV beat EPS estimates by 22.0%
Reported EPS: $6.03 vs estimate $4.94. Earnings strength supports our Fair Value of $299.96 (8.6% below current price).
ELV filed quarterly report (10-Q)
Quarterly update with interim financials. May signal changes to earnings trajectory and balance sheet health. View on SEC EDGAR →
ELV filed 8-K (material event)
8-K filings disclose material events — acquisitions, leadership changes, or guidance revisions that may affect valuation. View on SEC EDGAR →
ELV filed 8-K (material event)
8-K filings disclose material events — acquisitions, leadership changes, or guidance revisions that may affect valuation. View on SEC EDGAR →
ELV paid $1.7100/share dividend
Dividend Safety Grade: A. Payout ratio: 29.0%.
ELV filed 8-K (material event)
8-K filings disclose material events — acquisitions, leadership changes, or guidance revisions that may affect valuation. View on SEC EDGAR →
ELV filed 8-K (material event)
8-K filings disclose material events — acquisitions, leadership changes, or guidance revisions that may affect valuation. View on SEC EDGAR →
ELV missed EPS estimates by 1.4%
Reported EPS: $8.84 vs estimate $8.96. Our Fair Value of $299.96 may face downward pressure if the trend continues.
ELV filed quarterly report (10-Q)
Quarterly update with interim financials. May signal changes to earnings trajectory and balance sheet health. View on SEC EDGAR →
ELV filed 8-K (material event)
8-K filings disclose material events — acquisitions, leadership changes, or guidance revisions that may affect valuation. View on SEC EDGAR →
ELV paid $1.7100/share dividend
Dividend Safety Grade: A. Payout ratio: 29.0%.
ELV filed 8-K (material event)
8-K filings disclose material events — acquisitions, leadership changes, or guidance revisions that may affect valuation. View on SEC EDGAR →
ELV filed 8-K (material event)
8-K filings disclose material events — acquisitions, leadership changes, or guidance revisions that may affect valuation. View on SEC EDGAR →
ELV beat EPS estimates by 4.3%
Reported EPS: $11.97 vs estimate $11.48. Earnings strength supports our Fair Value of $299.96 (8.6% below current price).
ELV filed quarterly report (10-Q)
Quarterly update with interim financials. May signal changes to earnings trajectory and balance sheet health. View on SEC EDGAR →
ELV filed 8-K (material event)
8-K filings disclose material events — acquisitions, leadership changes, or guidance revisions that may affect valuation. View on SEC EDGAR →
ELV filed 8-K (material event)
8-K filings disclose material events — acquisitions, leadership changes, or guidance revisions that may affect valuation. View on SEC EDGAR →
ELV filed 8-K (material event)
8-K filings disclose material events — acquisitions, leadership changes, or guidance revisions that may affect valuation. View on SEC EDGAR →
ELV paid $1.7100/share dividend
Dividend Safety Grade: A. Payout ratio: 29.0%.
ELV filed annual report (10-K)
Annual filing with full-year financials. Our Altman Z-Score, Moat, and Fair Value models are derived from this data. View on SEC EDGAR →
ELV missed EPS estimates by 0.3%
Reported EPS: $3.84 vs estimate $3.85. Our Fair Value of $299.96 may face downward pressure if the trend continues.
ELV filed 8-K (material event)
8-K filings disclose material events — acquisitions, leadership changes, or guidance revisions that may affect valuation. View on SEC EDGAR →
Common questions about Elevance Health, Inc.
What is Elevance Health, Inc. stock price today?
Elevance Health, Inc. (ELV) stock price is $328.20 as of the latest market close, traded on the NYSE exchange.
What does Elevance Health, Inc. do?
Elevance Health, Inc., together with its subsidiaries, operates as a health benefits company in the United States. It operates in four segments: Health Benefits, CarelonRx, Carelon Services, and Corporate & Other. It offers a variety of health plans and services to individual, employer group risk-based and fee-based, BlueCard, Medicare, Medicaid, and FEP members; health products; a broad array of fee-based administrative managed care services; and specialty and other insurance products and services, such as stop loss, dental, vision, and supplemental health insurance benefits.
What is Elevance Health, Inc. market cap?
Elevance Health, Inc. has a market capitalization of $72.44B, classifying it as a large-cap stock in the Healthcare sector.
What sector and industry is ELV in?
Elevance Health, Inc. operates in the Healthcare sector, specifically within the Healthcare Plans industry. It trades on the NYSE under the ticker symbol ELV.
Is ELV stock overvalued or undervalued?
Based on our valuation model, Elevance Health, Inc. trades 9.4% above our fair value estimate — potentially overvalued.
- FairValueLabs Fair Value: $299.96
- Current Price: $328.20
- Valuation Zone: Fairly Valued
What is ELV stock forecast and analyst target price?
Based on 21 Wall Street analysts, the consensus price target for Elevance Health, Inc. is $378.19, implying upside of 15.2% from the current price.
- Analyst High Target: $474.00
- Analyst Low Target: $317.00
Note: Analyst targets are shown for reference and are not used in our valuation model.
Is Elevance Health, Inc. revenue and earnings growing?
Here are the analyst consensus growth estimates for Elevance Health, Inc.:
- Revenue growth (current year est.): -2.7%
- EPS growth (current year est.): -15.0%
- Revenue growth (next year est.): 2.5%
- EPS growth (next year est.): 12.8%
What are Elevance Health, Inc.'s key financial metrics?
| Metric | Latest | Trend |
|---|---|---|
| Revenue | $199.1B | Rising |
| Net Income | $5.7B | Stable |
| Free Cash Flow | $3.2B | Declining |
What is ELV's P/E ratio?
The price-to-earnings ratio measures how much investors pay per dollar of earnings:
- Trailing P/E (last 12 months): 13.9x
- Forward P/E (next 12 months est.): 11.3x
- FairValueLabs Fair P/E: 11.8x
How volatile is ELV stock?
Elevance Health, Inc. has a beta of 1.00, meaning it is roughly in line with overall market volatility. A beta above 1.0 indicates higher price swings relative to the S&P 500, while below 1.0 suggests more stability.
How much cash and debt does Elevance Health, Inc. have?
Elevance Health, Inc.'s balance sheet shows:
- Total Cash: $37.07B
- Total Debt: $31.84B
- Net Cash Position: $5.23B
A positive net cash position means the company holds more cash than debt, reducing financial risk.
What is Elevance Health, Inc.'s free cash flow?
Elevance Health, Inc. generated $4.32B in trailing twelve-month free cash flow (from $7.61B in operating cash flow). Free cash flow represents the cash available for dividends, buybacks, and debt reduction after all capital expenditures.
Does Elevance Health, Inc. pay a dividend, and is it safe?
Yes, Elevance Health, Inc. pays a regular dividend. Here are the key metrics:
- Dividend Yield: 1.6%
- Payout Ratio: 29.0%
- Consecutive Years Paid: 16
- 5-Year Dividend Growth: -17.6%
- FairValueLabs Safety Grade: A
Is Elevance Health, Inc. at risk of going bankrupt?
Elevance Health, Inc.'s Altman Z-Score is 2.83, placing it in the gray zone (1.8–3.0) — some financial uncertainty. The Z-Score uses five balance sheet ratios to predict bankruptcy probability within two years.
Does Elevance Health, Inc. have a durable competitive advantage?
Elevance Health, Inc. scores 3.4/5 stars (Narrow moat) in our moat analysis:
- ROIC Stability: 4/5
- Gross Margin Trend: 3/5
- Switching Costs: 3/5
A score above 3.5 suggests meaningful pricing power and a defensible market position.
What is ELV's return on equity (ROE)?
Elevance Health, Inc.'s return on equity is 12.1%. ROE measures how efficiently a company generates profits from shareholder equity. An ROE above 15% is generally considered strong, while below 10% may signal inefficiency.
How do I buy ELV stock?
ELV shares can be purchased through any brokerage account that provides access to the NYSE. Common steps:
- Open an account with a broker (e.g., Fidelity, Schwab, Interactive Brokers)
- Search for ticker symbol ELV
- Place a market or limit order for your desired number of shares
This is not investment advice. Always do your own research before buying any stock.
Is ELV a value stock or speculative?
FairValueLabs classifies Elevance Health, Inc. as Value Investment. It exhibits consistent profitability, reasonable valuation, and financial stability — characteristics of a traditional value investment.
Who is the CEO of Elevance Health, Inc.?
The current CEO of Elevance Health, Inc. is Ms. Gail Koziara Boudreaux.
What is ELV's earnings per share (EPS)?
Earnings per share measures the company's profit allocated to each outstanding share:
- Trailing EPS (last 12 months): $23.60
- Forward EPS (next 12 months est.): $29.07
- Analyst consensus EPS (this year): $25.75
- Analyst consensus EPS (next year): $29.05
Other Healthcare companies analyzed by FairValueLabs
FairValueLabs Disclaimer
All valuations, scores, ratings, and classifications on this page are produced by the FairValueLabs internal valuation system. They do not represent actual market value, guaranteed outcomes, or professional investment advice. These are analytical estimates for educational and research purposes only.
This is not financial advice. All data is sourced from SEC EDGAR public filings. Always consult a qualified financial advisor before making investment decisions.
Last updated: Apr 22, 2026. Data sources: SEC EDGAR (financial statements), Yahoo Finance (market data, analyst consensus). Data may not reflect the most recent quarter.
ELV analysis methodology: How we calculate fair value, Z-Scores, and moat ratings